Search | Clinical Trials Finder

Conditions: Excessive Daytime Sleepiness, Obstructive Sleep Apnea, Impaired Cognitive Function
Interventions: Solriamfetol, Placebo; Drug
Lead sponsor: Axsome Therapeutics, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 15
States / cities: Los Angeles, California • Santa Ana, California • Jacksonville, Florida + 11 more

Conditions: Narcolepsy, Obstructive Sleep Apnea, Excessive Daytime Somnolence, Excessive Sleepiness, Postpartum
Interventions: Solriamfetol 150 mg Oral Tablet; Drug
Lead sponsor: Axsome Therapeutics, Inc.; Industry
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Raleigh, North Carolina

Conditions: Narcolepsy, Cataplexy, Excessive Daytime Sleepiness
Interventions: AXS-12 (reboxetine), Placebo; Drug
Lead sponsor: Axsome Therapeutics, Inc.; Industry
Eligibility: 15 Years to 75 Years
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 24
States / cities: Phoenix, Arizona • Boulder, Colorado • Colorado Springs, Colorado + 20 more

Conditions: Sleep Apnea, Insomnia, Sleep Deprivation, Sleep Disorders, Circadian Rhythm, Sleepiness, Excessive Daytime, Fatigue
Interventions: Not listed
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 25 Years to 65 Years
Enrollment: 3,680 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Snoring, Mouth Breathing, Daytime Sleepiness, Periodontitis
Interventions: Oral appliance therapy plus scaling and root planing on left or right of mouth; Device
Lead sponsor: Texas A&M University; Other
Eligibility: 18 Years to 85 Years
Enrollment: 43 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Myotonic Dystrophy 1, Excessive Daytime Sleepiness
Interventions: Pitolisant Oral Tablet, Placebo oral tablet; Drug
Lead sponsor: Harmony Biosciences Management, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 11
States / cities: Irvine, California • Aurora, Colorado • Tampa, Florida + 8 more

Conditions: Parkinson's Disease
Interventions: Light exposure; Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 55 Years to 85 Years
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2018
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Sleep, Relaxation, Stress, Daytime Sleepiness
Interventions: Sleep Supplement; Dietary Supplement
Lead sponsor: Athletic Greens International; Industry
Eligibility: 22 Years to 59 Years
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Narcolepsy Type 1
Interventions: ALKS 2680 Dose 1, ALKS 2680 Dose 2, Placebo; Drug
Lead sponsor: Alkermes, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 14
States / cities: Brandon, Florida • Miami, Florida • Winter Park, Florida + 11 more

Conditions: Narcolepsy Type 1, Narcolepsy Type 2, Idiopathic Hypersomnia
Interventions: ORX750; Drug
Lead sponsor: Centessa Pharmaceuticals (UK) Limited; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 19
States / cities: Auburn, Alabama • Santa Ana, California • Miami, Florida + 14 more

Conditions: Parkinson's Disease, Sleep Disorder; Excessive Somnolence
Interventions: Bright Light Treatment (Sun Ray Sunbox SB-558), Dim red light (Sun Ray Sunbox SB-558); Device
Lead sponsor: Northwestern University; Other
Eligibility: Not listed
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Narcolepsy
Interventions: ADX-N05, Placebo; Drug
Lead sponsor: Jazz Pharmaceuticals; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 93 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 28
States / cities: Birmingham, Alabama • Phoenix, Arizona • Redwood City, California + 23 more

Conditions: Excessive Sleepiness, Shift-work Disorder
Interventions: Solriamfetol Oral Tablet, Placebo; Drug
Lead sponsor: Charles A. Czeisler, PhD, MD; Other
Eligibility: 18 Years to 64 Years
Enrollment: 84 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Multiple Sclerosis, Multiple Sclerosis Fatigue
Interventions: Solriamfetol, Placebo; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Parkinson Disease
Interventions: THN102 Dosage A, THN102 Dosage B, THN102 Dosage C; Drug
Lead sponsor: Theranexus; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 3
States / cities: Kansas City, Kansas • Boston, Massachusetts • Houston, Texas

Conditions: Schizophrenia
Interventions: Modafinil, Placebo; Drug
Lead sponsor: Veterans Medical Research Foundation; Other
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 1
States / cities: San Diego, California

Conditions: Narcolepsy Type 1
Interventions: ALKS 2680 Dose 1, ALKS 2680 Dose 2, Placebo; Drug
Lead sponsor: Alkermes, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 22
States / cities: Cullman, Alabama • Phoenix, Arizona • Los Angeles, California + 19 more

Conditions: Hypersomnia, Narcolepsy, Traumatic Brain Injury
Interventions: Sodium Oxybate Oral Solution [Xyrem]; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 64 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Insomnia, Blindness, Daytime Sleepiness
Interventions: Melatonin, Regular Sleep Schedule, Light; Drug · Behavioral
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years to 100 Years
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2012
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Obstructive Sleep Apnea
Interventions: Bright light therapy glasses; Device
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 50 Years to 65 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Obstructive Sleep Apnea
Interventions: TAK-925, Placebo; Drug
Lead sponsor: Millennium Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 67 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 18
States / cities: Alabaster, Alabama • Glendale, Arizona • Little Rock, Arkansas + 15 more

Conditions: Acid Reflux Disease, Obstructive Sleep Apnea
Interventions: Pantoprazole; Drug
Lead sponsor: University of Cincinnati; Other
Eligibility: 18 Years and older
Enrollment: 68 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2006
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Excessive Daytime Sleepiness, Narcolepsy, Obstructive Sleep Apnea/Hypopnea Syndrome, Chronic Shift Work Sleep Disorder
Interventions: Armodafinil 100 to 250 mg/day; Drug
Lead sponsor: Cephalon; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 743 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 74
States / cities: Birmingham, Alabama • Phoenix, Arizona • Hot Springs, Arkansas + 64 more

Conditions: Excessive Daytime Sleepiness, Narcolepsy
Interventions: Placebo, PF-03654746; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 21
States / cities: Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 15 more

Search by objective public record fields.

Solriamfetol's Effect on Cognitive Health in Apnea Participants During a Randomized Placebo-controlled Study

Evaluate Sunosi® PK in Breast Milk and Plasma of Healthy Postpartum Women Following Single Dose Oral Administration

A Study to Assess the Long-term Efficacy and Safety of AXS-12 (Reboxetine) in Subjects With Narcolepsy (ENCORE)

Adult Sleep Health in the Rural Appalachia and Mississippi Delta Region and Its Relationships With Cardiometabolic Health Disparities.

Does myTAP Oral Appliance Therapy Including a Mouth Shield Lessen Periodontitis in Mouth-Breathers Who Snore?

Safety and Efficacy of Pitolisant on Excessive Daytime Sleepiness and Other Non-Muscular Symptoms in Patients With Myotonic Dystrophy Type 1

Circadian Rhythms and Sleep-Wake Cycles in Parkinson's Disease

Sleep and Morning Wellbeing Study

A Study to Evaluate the Efficacy, Safety and Tolerability of ALKS 2680 in Adults With Narcolepsy Type 1 (Brilliance NT1 - 304)

A Long-term Extension Study of ORX750 in Participants With Narcolepsy and Idiopathic Hypersomnia

Light Therapy Treatment in Parkinson's Disease Patients With Daytime Somnolence

A Study of the Safety and Effectiveness of ADX-N05 for Excessive Daytime Sleepiness in Subjects With Narcolepsy

Clinical Trial of Solriamfetol for Excessive Sleepiness Related to Shift Work Disorder

Solriamfetol for the Treatment of Multiple Sclerosis Fatigue

Safety and Efficacy of THN102 in Patients With Parkinson's Disease and Excessive Daytime Sleepiness

Modafinil Augmentation Therapy for Excessive Daytime Sleepiness and Negative Symptoms in Patients With Schizophrenia

A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1

Evaluation of the Efficacy of Sodium Oxybate (Xyrem®) in Treatment of Post-traumatic Narcolepsy and Post-traumatic Hypersomnia

Melatonin for Circadian Sleep Disorders in the Blind

Bright Light Therapy for Residual Daytime Symptoms Associated With Obstructive Sleep Apnea

Study of TAK-925 in Participants With Obstructive Sleep Apnea (OSA) Who Are Experiencing Excessive Daytime Sleepiness (EDS) Despite Adequate Use of Continuous Positive Airway Pressure (CPAP)

Study of Pantoprazole for Sleepiness Associated With Acid Reflux and Sleep Apnea

Extension Study of the Safety and Efficacy of Armodafinil in the Treatment of Patients With Excessive Sleepiness

A Study Of A Novel Compound For Excessive Daytime Sleepiness Associated With Narcolepsy